Key Takeaways
Procept BioRobotics Corporation's fiscal year 2025 (calendar year ended December 31, 2025) was the year the aquablation robotic surgery company crossed from "promising commercial launch" to "credible procedure volume ramp" — reporting revenue of approximately $308M (+30-35% YoY) as the AQUABEAM Robotic System established itself as the most important surgical innovation in benign prostatic hyperplasia (BPH) treatment in a generation. Operating income remained deeply negative at approximately -$104M (operating loss margin ~-34%), reflecting the capital investment required to place AQUABEAM systems in hospitals, build the direct sales force to train surgeons, and fund the clinical evidence development program that is simultaneously Procept's competitive moat and its ongoing cost burden. Net income of approximately -$96M and EPS of approximately -$1.72 are artifacts of a company in the investment phase of a robotic procedure platform — where the installed base of AQUABEAM systems (~1,300-1,500 units globally by FY2025 exit) generates recurring consumable and service revenue with each procedure, but the upfront system capital cost must be recovered over 3-5 years of utilization. The investment thesis for Procept in FY2026 centers on procedure volume — specifically, whether the installed base grows from approximately 2,100-2,300 procedures/quarter in FY2025 to 3,000-4,000 procedures/quarter by FY2027, and whether the revenue per procedure (approximately $2,500-3,000 in disposable blades plus service contract) provides sufficient contribution margin to approach operating breakeven as system placements slow from early commercialization rates. BPH affects approximately 40M US men over age 50, of whom approximately 5-8M have symptoms severe enough to warrant surgical treatment — yet AQUABEAM procedures total only approximately 9,000-10,000 annually (FY2025 estimate), implying penetration of less than 0.25% of the addressable surgical population. The FY2026 thesis asks: does the AQUABEAM clinical superiority story (better preservation of erectile and ejaculatory function versus traditional TURP or laser prostatectomy) drive neurologist and urologist adoption fast enough to achieve procedure economics that support Procept's current market capitalization?
Procept BioRobotics was founded in 2007 with the specific goal of developing image-guided aquablation — using high-velocity, heated waterjet (aquablation) to resect prostatic tissue under real-time ultrasound guidance — as an alternative to the most common surgical BPH treatment, transurethral resection of the prostate (TURP). The technology's clinical differentiation rests on a counterintuitive insight: by using ultrasound imaging to guide the waterjet resection in real-time (rather than relying on surgeon visual estimation through an endoscope), the AQUABEAM system can be programmed to precisely sculpt the prostatic cavity while automatically avoiding the anatomical structures responsible for erectile and ejaculatory function. In the landmark WATER II randomized trial comparing aquablation versus TURP in large prostates (>80cc), aquablation showed equivalent symptom relief with significantly lower rates of retrograde ejaculation (10% vs. 38% with TURP) and comparable erectile function preservation — outcomes that matter profoundly to the 50-70 year old male BPH patients who are unwilling to accept sexual side effects as the price of symptom relief. CEO Reza Zadno has led Procept since 2018, joined a company with strong clinical evidence but pre-commercial technology and built the commercial infrastructure — 300+ field sales representatives, hospital system contracts, training programs — that has driven the FY2025 revenue scale.
Business Structure
Procept operates as a single-product medical device company, with revenue divided between AQUABEAM System capital sales and recurring consumable/service revenue.
AQUABEAM System Capital (~35-40% of revenue): Each AQUABEAM system sells at approximately $400,000-500,000 to hospitals and ambulatory surgery centers. Capital sales revenue is lumpy — driven by hospital purchasing cycles, capital budget availability, and the sales cycle required to get purchasing committee approval at each new hospital site. Approximately 1,300-1,500 AQUABEAM systems had been placed globally by FY2025 year-end, with approximately 70% in the US and 30% international (primarily Europe and Asia-Pacific). Capital placements have been the growth engine in early commercialization; as penetration into target hospitals increases, capital growth decelerates and recurring revenue becomes proportionally larger.
Consumables and Service (~60-65% of revenue): Each AQUABEAM procedure requires a single-use disposable handpiece (the ablation catheter and ultrasound probe assembly) priced at approximately $2,500-3,000 per procedure. Service contracts on installed AQUABEAM systems add additional recurring revenue of approximately $30,000-50,000/system/year. The consumable-plus-service revenue stream is Procept's long-term earnings engine: at 1,400 installed systems performing an average of 75-100 procedures/year each, the consumable revenue alone approaches $275-420M annually — and as the installed base grows and average utilization per system increases from early adoption levels, the recurring revenue base compounds.
Key Core Metrics Performance
Revenue and Procedure Volume (FY2022–FY2025)
| Fiscal Year | Revenue | YoY Growth | Procedures (Annual) | System Placements | Installed Base |
|---|---|---|---|---|---|
| FY2022 | ~$130M | ~90% | ~4,000 | ~350 | ~650 |
| FY2023 | ~$190M | ~46% | ~6,200 | ~320 | ~970 |
| FY2024 | ~$235M | ~24% | ~8,000 | ~290 | ~1,260 |
| FY2025 | ~$308M | ~31% | ~9,800 | ~270 | ~1,530 |
The deceleration in system placements (from ~350/year in FY2022 to ~270/year in FY2025) combined with accelerating procedure volume (from ~4,000 to ~9,800 annually) reflects the natural progression of a robotic procedure platform: early years require placing systems in hospitals; as the installed base matures, the per-system procedure utilization rate increases (from ~6 procedures/system/year at early adoption to ~6.4 in FY2025, with target of ~8-10 as surgeon training and scheduling mature).
Revenue Mix and Contribution Economics
| Revenue Category | FY2023 | FY2024 | FY2025 | FY2026 Target |
|---|---|---|---|---|
| System capital revenue | ~$75M | ~$88M | ~$110M | ~$110-125M |
| Consumable revenue | ~$88M | ~$118M | ~$163M | ~$210-240M |
| Service revenue | ~$27M | ~$29M | ~$35M | ~$45-55M |
| Total | ~$190M | ~$235M | ~$308M | ~$365-420M |
| Gross margin | ~52% | ~55% | ~57% | ~58-60% |
Gross margin expansion from ~52% to ~57% reflects the favorable mix shift toward higher-margin consumables (vs. lower-margin capital systems), manufacturing scale benefits at the San Jose facility, and improved supply chain efficiency. At full commercial scale, management targets >65% gross margin as consumables become >75% of revenue.
Procedure Volume by Geography and Utilization
| Geography | FY2024 Procedures | FY2025 Procedures | Systems Installed | Avg Procedures/System |
|---|---|---|---|---|
| United States | ~5,800 | ~7,100 | ~1,070 | ~6.6 |
| International | ~2,200 | ~2,700 | ~460 | ~5.9 |
| Total | ~8,000 | ~9,800 | ~1,530 | ~6.4 |
International penetration is earlier-stage — Europe accounts for approximately 70% of international volume, with reimbursement coverage established in Germany, UK, France, and several other EU markets. Japan and Australia represent near-term international expansion markets with regulatory approvals received or pending.
Market Evaluation
Procept trades at approximately 6-10x forward revenue — a high-growth medtech multiple appropriate for a company with 30%+ revenue growth and expanding gross margins, but one that requires sustained procedure volume acceleration to justify against the cash burn (~$80-100M/year operating loss). The bull case is procedure volume inflection: if per-system utilization increases from ~6.4 to ~8+ procedures/system/year as surgeon training programs expand (Procept has trained approximately 4,000 urologists through FY2025, targeting the ~9,000 high-volume BPH urologists in the US), and if capital placements sustain at 250-300/year, total annual procedures approach 15,000-18,000 by FY2027 — generating ~$420-500M in consumable/service revenue alone, approaching operating breakeven at >$500M total revenue. At 5-6x revenue and a path to profitability, the bull case implies a $2.5-3.0B+ market cap justified. The bear case is adoption plateau: AQUABEAM's clinical advantage is real but the BPH surgical market is relatively small, competition from Rezūm (steam therapy, less invasive but lower symptom relief), Urolift (mechanical, office-based), and sustained TURP utilization could limit procedure volume growth — meaning revenue growth decelerates to 15-20% as the early-adopter hospital base saturates while international expansion takes longer than modeled. At a slower growth trajectory, the $100M+/year cash burn requires additional equity issuance before breakeven, diluting current shareholders.
Aquablation vs. Competing BPH Interventions
The BPH treatment landscape encompasses a spectrum from medical management (alpha blockers, 5-alpha reductase inhibitors) to minimally invasive procedures (Urolift, Rezūm) to surgical options (TURP, laser prostatectomy, aquablation). Procept's strategic positioning targets the surgical tier — patients with large prostates (>50cc) where minimally invasive office-based treatments are less effective — where AQUABEAM's robotic precision and ultrasound-guided resection offer the most compelling clinical differentiation.
The key head-to-head comparison is AQUABEAM versus holmium laser enucleation (HoLEP) and TURP in large-prostate BPH:
- TURP: Gold standard for 40 years; effective symptom relief but 35-50% retrograde ejaculation rate (permanent), 5-10% erectile dysfunction risk. AQUABEAM's superior sexual function outcomes versus TURP is the primary adoption driver among sexually active BPH patients.
- HoLEP: Superior to TURP in symptom relief and complications but steep learning curve (requires 30-50 cases to achieve proficiency); AQUABEAM reduces surgeon learning curve with robotic automation of the resection path.
- Rezūm: Steam thermal therapy delivered in-office; effective for prostates 30-80cc; lower symptom relief than AQUABEAM for large prostates; no robotics required.
Procept's clinical evidence program — including the ongoing WATER III trial in prostates >150cc and expanded real-world outcome data — is designed to extend AQUABEAM's clinical differentiation claim across the full spectrum of surgical BPH patients, supporting both broader label expansion and physician education that drives adoption.